Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

allogeneic anti-HA-2 TCR-engineered T cells TSC-101

A preparation of donor-derived T lymphocytes that have been genetically engineered to express a T-cell receptor (TCR) specific for HLA-A*02:01-restricted minor histocompatibility antigen HA-2 (HA2), with potential immunomodulating and antineoplastic activities. Following allogeneic haploidentical hematopoietic cell transplantation (HCT) in HLA-A*02:01 positive patients, allogeneic anti-HA-2 TCR-engineered T cells TSC-101 specifically recognize and bind to HA-2 expressed on tumor cells. This may lead to cytotoxic T-lymphocyte (CTL)-mediated elimination of tumor cells expressing HA-2. HA-2 is a lineage-specific antigen found on leukemia cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic T-cell receptor-engineered T cells TSC-101
HA-2-targeting TCR-T cells TSC-101
T-cell receptor engineered donor T Cells TSC-101
Code name:TSC 101
TSC-101
TSC101
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search